Rheumatoid arthritis does not have the latest therapeutic drugs, at present, the newer therapeutic drugs for rheumatoid arthritis are tofacitib and baricitinib. JAK inhibitors such as tofacitib and baricitinib are relatively new drugs in the treatment of rheumatoid arthritis. By inhibiting the JAK enzyme, they can affect the hematopoietic process of cells and cellular immune function, and the latest progress of related therapeutic research has shown that tofacitib has a good effect on single-drug treatment, and baricitinib can significantly improve the fatigue symptoms of rheumatoid arthritis patients. Rheumatoid arthritis treatment should be individualized according to the patient’s specific situation, tofacitib, baricitinib and other new drugs may not be absolutely suitable for a particular rheumatoid arthritis patients. Drugs should be used under the guidance of a physician, and it is recommended that patients go to the rheumatology and immunology departments of regular hospitals for detailed consultation.